The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV (2019)

Peer-Reviewed Study · Akamatsu H, Ninomiya K, Kenmotsu H, Morise M, Daga H, Goto Y, et al. (Int J Clin Oncol 2019;24:855-874) · May 2, 2019

Akamatsu H et al., 2019-05-02: National clinical practice guideline from the Japanese Lung Cancer Society for stage IV NSCLC. Its first reference is the Cochrane review CHJ-01, and the guideline adopts its finding and its 9% one-year survival gain in its recommendations.

A meta-analysis showed that cytotoxic chemotherapy significantly prolonged overall survival (OS) compared with best supportive care (BSC)

Section on cytotoxic chemotherapy (reference 1 = CD007309)

Akamatsu H et al., 2019-05-02: National clinical practice guideline from the Japanese Lung Cancer Society for stage IV NSCLC. Its first reference is the Cochrane review CHJ-01, and the guideline adopts its finding and its 9% one-year survival gain in its recommendations. Direct documented instance of a national guideline body adopting, not dismissing, a Cochrane chemotherapy review. Funder: Japan Lung Cancer Society (society guideline); individual author disclosures are in the paper. The guideline's reference 1 is 'Cochrane Database Syst Rev. 2010;2010(5):CD007309' – i.e. CHJ-01. No example of a Cochrane review being 'ignored or dismissed' was found in the record searched. Study type: other.